Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

French Agency To Boost EU Role & Open Up To Outside World

Executive Summary

France’s medicines and medical devices regulator wants to build up its role in the EU regulatory system, make its inner workings more accessible to stakeholders and the outside world, and improve the way it deals with medicine shortages.

You may also be interested in...



France OKs Early Access To Tecentriq For SCLC Pending EU Approval

Tecentriq has become the second authorized medicine to be made available for an unapproved indication under modifications to France’s early access program. Patients with small cell lung cancer can now be given the product pending EU approval of its use in this condition.

Make Them In Europe: The French Solution To Drug Shortages

The French Senate has produced a set of recommendations for tackling the growing problem of medicine shortages in France and the rest of Europe. The industry body Leem says shortages have many causes and that it will work with other stakeholders to find long-term solutions.

EU Wants Legislative Review To Support ‘World Class’ Pharmaceutical Industry

The European health commissioner has told members of parliament that a balance needs to be struck between promoting innovation and maximizing access to medicines across the EU member states.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS125407

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel